# Sermorelin: The GHRH(1-29) Secretagogue — Safety Record and Research

> Sermorelin is the GHRH(1-29) growth-hormone-releasing peptide. A cited digest of its mechanism, half-life, safety record, and body-composition findings.

The line is short: a fragment of the brain's own "make growth hormone" signal, formerly an approved pediatric drug, now compounded. Every figure on this board is carried back to the study that measured it.

## The short version

Sermorelin is a small peptide — 29 amino acids — that copies the front end of GHRH (the brain's own "make growth hormone" signal). It is a secretagogue (something that tells a gland to release its hormone): it nudges the pituitary to put out the body's own growth hormone (GH) in natural bursts, which then raises IGF-1 (a growth signal the liver makes when GH rises). It was once an FDA-approved medicine for children who grew too slowly, was pulled from the US market in 2008 for business reasons — not safety — and is now made by compounding pharmacies. This site is a plain-English reading of what the studies actually found, with every number sourced.

## Sermorelin: The GHRH(1-29) Peptide

Sermorelin is the amino-terminal 1-29 fragment of growth hormone-releasing hormone — the shortest piece of the 44-residue parent hormone that still keeps full activity at the GHRH receptor [3][14]. In the literature it carries several names: GHRH(1-29), GRF(1-29), GRF(1-29)NH2. As a **sermorelin peptide**, it is a synthetic chain of 3357.9 daltons, built to mimic a signal the body already uses every night.

Its mechanism is upstream, not replacement. Sermorelin binds the GHRH receptor on anterior-pituitary somatotrophs (the GH-producing cells), switching on the adenylate-cyclase / cAMP / protein-kinase-A pathway that drives synthesis and release of the body's own GH [14]. Because it acts on the gland rather than supplying outside GH, the natural brakes stay intact: somatostatin (the hormone that inhibits GH) and IGF-1 feedback keep the pulse pattern physiologic [4][14]. That distinction — stimulating an own-supply versus replacing it — is the whole reason the molecule was studied as a more physiologic approach to adult-onset GH insufficiency than recombinant GH [4]. Read the full account of [how sermorelin works](/) below, or jump to [what the research says](/research).

## Sermorelin Acetate

The compounded and research form is sermorelin acetate — the amidated acetate salt of the GHRH(1-29) fragment (CAS 86168-78-7; the acetate salt, CAS 114466-38-5). Amidation of the C-terminus is part of what gives the short fragment its full receptor activity. It is supplied as a lyophilized (freeze-dried) powder because aqueous peptide solutions degrade; once reconstituted it is refrigerated, and compounded preparations are made under USP sterile-compounding standards. None of that is a dosing instruction — it is the handling context the literature describes.

## What the Research Says About Sermorelin

The strongest evidence sits where the molecule was originally approved. In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without driving IGF-1 above the normal range [1]. That is a controlled, on-label result.

In adults the signals are real but narrower. In healthy older men (mean age 68), twice-daily GHRH(1-29) at 0.5 mg and 1 mg for 14 days produced dose-related rises in 24-hour GH and IGF-1; after the high dose, their GH/IGF-1 parameters no longer differed from those of young men, with no change in fasting glucose [2]. Over 16 weeks, age-advanced men and women self-injecting an analog of the fragment nightly showed rising IGF-1 and IGFBP-3, with no change in blood pressure or body weight [9]. The honest counterweight: an Annals of Internal Medicine editorial judged the use of GH secretagogues to slow aging "not yet ready for prime time" [5]. Both statements are true at once, which is the point of reading the record rather than the marketing.

The topics branch from here: [doses used in research](/dosage), [sermorelin half-life](/half-life), [sermorelin and body composition](/body-composition), and [side effects reported in studies](/research). The [common questions about sermorelin](/faq) collect the rest.

## The status board: formerly approved, now compounded

Sermorelin's regulatory history is the single fact most often misstated, so it belongs on the front of the board. It was a genuine FDA-approved prescription drug for evaluating and treating growth-hormone deficiency and short stature in children [1]. It was withdrawn from the US market in 2008 for commercial reasons — not because of any safety or efficacy problem. "Formerly approved" is not "never approved," and it is not "banned."

What it is today: a compounded preparation. Sermorelin is treated as a long-standing Category 1 bulk drug substance under FDA's interim Section 503A framework (with final guidance issued in January 2025), the category against which the agency does not intend enforcement action. It is not a currently-marketed FDA-approved finished drug, and it is not a controlled substance under the Controlled Substances Act. In sport, GH secretagogues — including GHRH analogs like sermorelin — are prohibited by WADA. Those four lines are the honest status board: formerly approved, now compounded, not scheduled, prohibited in competition.

## What sermorelin is not

Three boundaries keep the reading clean. First, the adult body-composition and anti-aging claims attached to sermorelin outrun the controlled evidence — the credible fat and IGF-1 numbers in this drug class largely belong to the related analog tesamorelin, not to sermorelin itself [6][11], and this site keeps that line drawn on its [sermorelin and body composition](/body-composition) page. Second, oral, sublingual, and troche "sermorelin" products are widely criticized as ineffective, consistent with the very low (~3-5%) absorption reported even for the intranasal route [3]. Third, the research-grade sermorelin this digest describes is supplied for laboratory work — not as a finished medicine to self-administer — which is why every figure here is reported as "studied at X in [population]" and never as a dose to take.

## What does sermorelin do to the body?

It binds GHRH receptors on pituitary somatotrophs and stimulates the body's own pulsatile growth-hormone release, which raises liver-made IGF-1 [14]. Because it acts upstream — on the gland rather than supplying outside hormone — somatostatin and IGF-1 feedback stay intact, preserving the natural burst pattern of secretion rather than flattening it [4].

---

A transit-board reading of the sermorelin literature — the GHRH(1-29) findings routed line by line, each GH and IGF-1 figure carried back to its study, the body-composition evidence marked as tesamorelin where it belongs, and the stop where the long-term adult data run out left openly unserviced; no clinic at this board and nothing here dosed, dispensed, or sold.